SK Chemicals Co Ltd stock (KR7285130001): Q1 loss widens as chemical and vaccine segments face pressure

SK Chemicals Co Ltd reported a wider consolidated operating loss in the first quarter, driven by weaker performance in its Green Chemical and Life Sciences segments, according to recent earnings data.

SK Chemicals Co Ltd reported a consolidated operating loss of 18.9 billion won in the first quarter, compared with a 24.3 billion won profit in the same period a year earlier, according to a recent earnings note from Marketscreener on May 6, 2026.Marketscreener as of May 6, 2026 The result reflects ongoing pressure in both its Green Chemical and Life Sciences segments, even as the company continues to invest in advanced recycling and specialty materials.

As of: 09.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: SK Chemicals Co Ltd
• Sector/industry: Specialty chemicals and life sciences
• Headquarters/country: South Korea
• Core markets: Domestic South Korean market plus exports to the United States, Europe, China and Japan
• Key revenue drivers: Green Chemical products (high?performance copolyester resins, CR?PET, bio?polyols) and Life Sciences (vaccines, infusion solutions, natural and synthetic pharmaceuticals)
• Home exchange/listing venue: Korea Exchange (KRX), ticker 28513K
• Trading currency: Korean won (KRW)

SK Chemicals Co Ltd: core business model

SK Chemicals Co Ltd is a South Korean specialty?chemicals and life?sciences company that supplies materials and pharmaceutical products to industrial and healthcare customers worldwide.Marketscreener as of May 6, 2026 The firm operates through two main segments: Green Chemical and Life Sciences, each targeting different end?markets but sharing a focus on higher?value, often environmentally oriented products.

The Green Chemical segment produces high?performance copolyester resins, dimethyl terephthalate (DMT), coating agents, polyester resins for adhesives, bio?polyols and chemically recycled polyethylene terephthalate (CR?PET), among related raw materials.Marketscreener as of May 6, 2026 These materials are used in packaging, automotive, electronics and construction, where demand is sensitive to global industrial activity and raw?material costs.

The Life Sciences segment focuses on vaccines, infusion solutions and pharmaceuticals, including proprietary vaccines such as Boostrix and a portfolio of natural and synthetic drugs.Marketscreener as of May 6, 2026 This segment ties SK Chemicals to global healthcare demand, regulatory approvals and vaccine?related intellectual?property developments, including its involvement in the Pfizer v. Sanofi vaccine?patent dispute as a manufacturing partner.PatSnap Eureka as of May 6, 2026

Main revenue and product drivers for SK Chemicals Co Ltd

Within the Green Chemical segment, SK Chemicals’ key revenue drivers include high?performance copolyester resins and CR?PET, which are positioned as more sustainable alternatives to conventional plastics.Marketscreener as of May 6, 2026 The company is part of a broader South Korean push to commercialize advanced recycling technologies, with SK Chemicals, LG Chem and GS Caltex all accelerating efforts to turn waste plastic into feedstock for new chemical products.Biggo as of May 6, 2026

These green?chemistry initiatives are intended to support long?term growth by aligning with global environmental regulations and brand?owner sustainability targets, particularly in markets such as the United States and Europe.Biggo as of May 6, 2026 However, near?term profitability can be pressured by volatile oil and petrochemical feedstock prices, as well as by the capital intensity of building and scaling advanced recycling capacity.

In the Life Sciences segment, SK Chemicals’ vaccines and infusion?solution businesses contribute to revenue, with the company also supplying natural and synthetic pharmaceutical products to domestic and international customers.Marketscreener as of May 6, 2026 The firm’s subsidiary SK Bioscience, listed separately on the Korea Exchange under ticker 302440, further expands its footprint in vaccine development and manufacturing, adding another layer of exposure to global immunization demand and regulatory timelines.Investing.com as of May 6, 2026

Why SK Chemicals Co Ltd matters for US investors

For US investors, SK Chemicals offers indirect exposure to both the global specialty?chemicals complex and the international vaccine and pharmaceutical supply chain.Marketscreener as of May 6, 2026 The company sells products in the United States, Europe, China and Japan, meaning its performance is influenced by US industrial demand, healthcare spending and trade dynamics.

US?listed investors may encounter SK Chemicals through Korean?equity ETFs or via direct exposure to SK Bioscience, which is a subsidiary and a separate listed entity.Investing.com as of May 6, 2026 The broader SK Group ecosystem, including SK Innovation and other affiliates, also links SK Chemicals to global energy, battery materials and petrochemical trends that can affect input costs and downstream demand.

Conclusion

SK Chemicals Co Ltd faces a challenging near?term environment, as evidenced by its wider consolidated operating loss in the first quarter of 2026, even while it continues to invest in green chemistry and life?sciences capabilities.Marketscreener as of May 6, 2026 The company’s dual focus on advanced recycling and vaccines positions it at the intersection of environmental and healthcare megatrends, but also exposes it to cyclical industrial demand, raw?material volatility and regulatory risk.

For US investors, SK Chemicals represents a niche but strategically positioned player in the global specialty?chemicals and vaccine?supply chain landscape, with performance closely tied to Korean and global macroeconomic conditions.Marketscreener as of May 6, 2026 The stock’s trajectory will likely depend on how effectively management can balance near?term margin pressures with long?term growth in green materials and life?sciences products, without committing to any specific investment recommendation.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.